UA54169A - Противоязвенное средство "прополтин" - Google Patents
Противоязвенное средство "прополтин" Download PDFInfo
- Publication number
- UA54169A UA54169A UA2002054389A UA200254389A UA54169A UA 54169 A UA54169 A UA 54169A UA 2002054389 A UA2002054389 A UA 2002054389A UA 200254389 A UA200254389 A UA 200254389A UA 54169 A UA54169 A UA 54169A
- Authority
- UA
- Ukraine
- Prior art keywords
- ulcer
- propoltin
- propolis
- effect
- phenolic
- Prior art date
Links
- 208000025865 Ulcer Diseases 0.000 title abstract description 8
- 231100000397 ulcer Toxicity 0.000 title abstract description 8
- 241000241413 Propolis Species 0.000 claims abstract description 14
- 229940069949 propolis Drugs 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000013543 active substance Substances 0.000 claims abstract description 8
- 229910002012 Aerosil® Inorganic materials 0.000 claims abstract description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000003699 antiulcer agent Substances 0.000 claims description 8
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 6
- 239000001095 magnesium carbonate Substances 0.000 claims description 6
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 4
- 238000012876 topography Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 2
- OGWLTJRQYVEDMR-UHFFFAOYSA-F tetramagnesium;tetracarbonate Chemical compound [Mg+2].[Mg+2].[Mg+2].[Mg+2].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O OGWLTJRQYVEDMR-UHFFFAOYSA-F 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 22
- 229940079593 drug Drugs 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 239000002775 capsule Substances 0.000 description 14
- 230000000767 anti-ulcer Effects 0.000 description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 235000013824 polyphenols Nutrition 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 229960000620 ranitidine Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- 208000008469 Peptic Ulcer Diseases 0.000 description 5
- 229930003427 Vitamin E Natural products 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- XBCXJKGHPABGSD-UHFFFAOYSA-N methyluracil Natural products CN1C=CC(=O)NC1=O XBCXJKGHPABGSD-UHFFFAOYSA-N 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 208000011906 peptic ulcer disease Diseases 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 229940046009 vitamin E Drugs 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000009341 apiculture Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011287 therapeutic dose Methods 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000001553 hepatotropic effect Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- YXXXFTZMJKUYSM-UHFFFAOYSA-H 5-hydroxy-2,8,9-trioxa-1-bismabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Bi+3].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YXXXFTZMJKUYSM-UHFFFAOYSA-H 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000867418 Morion Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002625 immunotoxic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008756 pathogenetic mechanism Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 229930191173 propolin Natural products 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000002731 stomach secretion inhibitor Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Противоязвенное средство на основе прополиса в качестве активно действующего вещества содержит фенольный гидрофильный препарат прополиса, в качестве вспомогательных веществ – магния карбонат основной и аэросил.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA2002054389A UA54169A (ru) | 2002-05-29 | 2002-05-29 | Противоязвенное средство "прополтин" |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA2002054389A UA54169A (ru) | 2002-05-29 | 2002-05-29 | Противоязвенное средство "прополтин" |
Publications (1)
Publication Number | Publication Date |
---|---|
UA54169A true UA54169A (ru) | 2003-02-17 |
Family
ID=74305814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA2002054389A UA54169A (ru) | 2002-05-29 | 2002-05-29 | Противоязвенное средство "прополтин" |
Country Status (1)
Country | Link |
---|---|
UA (1) | UA54169A (ru) |
-
2002
- 2002-05-29 UA UA2002054389A patent/UA54169A/ru unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2438693C2 (ru) | Способы лечения и предупреждения мукозита производными антоцианидина | |
US20080193531A1 (en) | Compositions for improving gastrointestinal nutrient and drug absorption | |
RU98111594A (ru) | Фармацевтические композиции, включающие флурбипрофен | |
UA90507C2 (ru) | Мукоадгезивная композиция для приготовления медицинских средств и фармацевтических композиций | |
KR930005619A (ko) | 위장 질환 치료용 약제 | |
JP2002543107A (ja) | 葉酸補給物 | |
US3094464A (en) | Aspirin-antacid polysiloxane tablet | |
KR0147855B1 (ko) | 골형성 촉진제 | |
UA54169A (ru) | Противоязвенное средство "прополтин" | |
JP4791358B2 (ja) | 真菌の重感染と真菌の再発の処置のためのアスコルビン酸を含んでなる製薬学的組成物 | |
CN108136210B (zh) | 含有单宁的组合物 | |
JPWO2006043336A1 (ja) | 胃粘膜疾患の治療又は予防のための組成物 | |
US4976970A (en) | Pharmaceutical composition and method for treatment of digestive disorders | |
DE3688787D1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
RU2216320C1 (ru) | Средство фарингал для профилактики и лечения инфекционно-воспалительных заболеваний ротоглотки | |
JPS60224615A (ja) | 調剤組成物 | |
JPH0466205B2 (ru) | ||
US5874065A (en) | Oral anti-acid paste and methods of use | |
RU2141308C1 (ru) | Лекарственное средство для лечения грибковых заболеваний полости рта | |
US5010107A (en) | Method and composition for achieving anticarcinogenic activity | |
RU2634251C1 (ru) | Жевательная таблетка | |
RU2310343C1 (ru) | Биологически активная добавка для профилактики заболеваний мужской мочеполовой сферы | |
RU2265437C2 (ru) | Способ лечения заболеваний желудка и двенадцатиперстной кишки, вызванных helicobacter pylori | |
RU2120293C1 (ru) | Противовоспалительное средство | |
RU2160104C2 (ru) | Способ лечения язвенной болезни и лекарственный препарат для его осуществления |